Выбор редакции

Big BioPharma Stock Buybacks: Are There Better Alternatives?

Big Pharma remains a highly profitable cash cow in spite of its well-known R&D challenges and perennial patent cliffs.  One of the biggest questions their Boards wrestle with is what to do with all the cash. In recent years, plowing it back into internal R&D hasn’t been the preferred option given [...]